肺动脉高压的药物治疗 - Suppr

Suppr

超能文献

Pharmacotherapy for pulmonary arterial hypertension.

作者信息

Burki Talha Khan

出版信息

Lancet Respir Med. 2020 Nov;8(11):e81. doi: 10.1016/S2213-2600(20)30394-5. Epub 2020 Aug 25.

DOI:10.1016/S2213-2600(20)30394-5

PMID:32857988

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7447256/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c9b/7447256/f678bdd594df/fx1_lrg.jpg

相似文献

Pharmacotherapy for pulmonary arterial hypertension.

Lancet Respir Med. 2020 Nov;8(11):e81. doi: 10.1016/S2213-2600(20)30394-5. Epub 2020 Aug 25.

Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.

J Am Coll Cardiol. 2021 Oct 5;78(14):1393-1403. doi: 10.1016/j.jacc.2021.07.057.

Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play.

Arch Bronconeumol (Engl Ed). 2019 Feb;55(2):102-103. doi: 10.1016/j.arbres.2018.03.010. Epub 2018 Jul 27.

[Pulmonary hypertension].

Dtsch Med Wochenschr. 2012 Oct;137(40):2026-8. doi: 10.1055/s-0032-1305308. Epub 2012 Sep 28.

Update on pharmacotherapy for pulmonary hypertension.

Med J Aust. 2016 Sep 19;205(6):271-6. doi: 10.5694/mja16.00468.

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension.

BMC Pulm Med. 2017 Oct 26;17(1):135. doi: 10.1186/s12890-017-0480-9.

Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome.

Can J Cardiol. 2021 Aug;37(8):1286-1288. doi: 10.1016/j.cjca.2021.01.023. Epub 2021 Feb 2.

Outcomes of selexipag for treatment of pulmonary arterial hypertension in an Asian population.

Ann Acad Med Singap. 2023 Apr 27;52(4):219-221. doi: 10.47102/annals-acadmedsg.2022474.

Use of an implantable wireless pulmonary pressure monitor during transition of therapy in pulmonary arterial hypertension.

J Heart Lung Transplant. 2019 Feb;38(2):227-230. doi: 10.1016/j.healun.2018.11.011. Epub 2018 Nov 24.

Selexipag for the treatment of pulmonary arterial hypertension.

Expert Rev Respir Med. 2021 May;15(5):583-595. doi: 10.1080/17476348.2021.1866990. Epub 2020 Dec 31.

引用本文的文献

Otud6b induces pulmonary arterial hypertension by mediating the Calpain-1/HIF-1α signaling pathway.

Cell Mol Life Sci. 2024 Jun 15;81(1):258. doi: 10.1007/s00018-024-05291-3.

Upregulation of eIF2α by mA modification accelerates the proliferation of pulmonary artery smooth muscle cells in MCT-induced pulmonary arterial hypertension rats.

J Cardiovasc Transl Res. 2024 Jun;17(3):598-608. doi: 10.1007/s12265-023-10458-7. Epub 2023 Nov 16.

Mitochondrial dysfunction in pulmonary arterial hypertension.

Front Physiol. 2022 Dec 14;13:1079989. doi: 10.3389/fphys.2022.1079989. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Pharmacotherapy for pulmonary arterial hypertension.

Lancet Respir Med. 2020 Nov;8(11):e81. doi: 10.1016/S2213-2600(20)30394-5. Epub 2020 Aug 25.

Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.

J Am Coll Cardiol. 2021 Oct 5;78(14):1393-1403. doi: 10.1016/j.jacc.2021.07.057.

Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play.

Arch Bronconeumol (Engl Ed). 2019 Feb;55(2):102-103. doi: 10.1016/j.arbres.2018.03.010. Epub 2018 Jul 27.

[Pulmonary hypertension].

Dtsch Med Wochenschr. 2012 Oct;137(40):2026-8. doi: 10.1055/s-0032-1305308. Epub 2012 Sep 28.

Update on pharmacotherapy for pulmonary hypertension.

Med J Aust. 2016 Sep 19;205(6):271-6. doi: 10.5694/mja16.00468.

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension.

BMC Pulm Med. 2017 Oct 26;17(1):135. doi: 10.1186/s12890-017-0480-9.

Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome.

Can J Cardiol. 2021 Aug;37(8):1286-1288. doi: 10.1016/j.cjca.2021.01.023. Epub 2021 Feb 2.

Outcomes of selexipag for treatment of pulmonary arterial hypertension in an Asian population.

Ann Acad Med Singap. 2023 Apr 27;52(4):219-221. doi: 10.47102/annals-acadmedsg.2022474.

Use of an implantable wireless pulmonary pressure monitor during transition of therapy in pulmonary arterial hypertension.

J Heart Lung Transplant. 2019 Feb;38(2):227-230. doi: 10.1016/j.healun.2018.11.011. Epub 2018 Nov 24.

Selexipag for the treatment of pulmonary arterial hypertension.

Expert Rev Respir Med. 2021 May;15(5):583-595. doi: 10.1080/17476348.2021.1866990. Epub 2020 Dec 31.

引用本文的文献

Otud6b induces pulmonary arterial hypertension by mediating the Calpain-1/HIF-1α signaling pathway.

Cell Mol Life Sci. 2024 Jun 15;81(1):258. doi: 10.1007/s00018-024-05291-3.

Upregulation of eIF2α by mA modification accelerates the proliferation of pulmonary artery smooth muscle cells in MCT-induced pulmonary arterial hypertension rats.

J Cardiovasc Transl Res. 2024 Jun;17(3):598-608. doi: 10.1007/s12265-023-10458-7. Epub 2023 Nov 16.

Mitochondrial dysfunction in pulmonary arterial hypertension.

Front Physiol. 2022 Dec 14;13:1079989. doi: 10.3389/fphys.2022.1079989. eCollection 2022.